498 related articles for article (PubMed ID: 21878657)
21. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
22. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
[TBL] [Abstract][Full Text] [Related]
23. A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
Box C; Mendiola M; Gowan S; Box GM; Valenti M; Brandon Ade H; Al-Lazikani B; Rogers SJ; Wilkins A; Harrington KJ; Eccles SA
Eur J Cancer; 2013 Jul; 49(11):2512-21. PubMed ID: 23582742
[TBL] [Abstract][Full Text] [Related]
24. A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC).
Low JL; Lau DP; Zhang X; Kwang XL; Rohatgi N; Chan JV; Chong FT; Wong SQR; Leong HS; Thangavelu MT; Rikka S; Skanderup AMJ; Tan DSW; Periyasamy G; Koh JLY; Iyer NG; DasGupta R
EBioMedicine; 2021 Feb; 64():103220. PubMed ID: 33529999
[TBL] [Abstract][Full Text] [Related]
25. Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma.
Kramer B; Schell A; Aderhold C; Huber L; Mueller CE; Rotter N; Birk R
Anticancer Res; 2020 Jul; 40(7):3847-3855. PubMed ID: 32620624
[TBL] [Abstract][Full Text] [Related]
26. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
27. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
[TBL] [Abstract][Full Text] [Related]
28. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
29. Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway.
Maseki S; Ijichi K; Tanaka H; Fujii M; Hasegawa Y; Ogawa T; Murakami S; Kondo E; Nakanishi H
Br J Cancer; 2012 Mar; 106(6):1196-204. PubMed ID: 22315058
[TBL] [Abstract][Full Text] [Related]
30. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells.
Sun Q; Ming L; Thomas SM; Wang Y; Chen ZG; Ferris RL; Grandis JR; Zhang L; Yu J
Oncogene; 2009 Jun; 28(24):2348-57. PubMed ID: 19421143
[TBL] [Abstract][Full Text] [Related]
31. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.
Shin DH; Min HY; El-Naggar AK; Lippman SM; Glisson B; Lee HY
Mol Cancer Ther; 2011 Dec; 10(12):2437-48. PubMed ID: 21980128
[TBL] [Abstract][Full Text] [Related]
32. Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways.
Axelrod MJ; Mendez RE; Khalil A; Leimgruber SS; Sharlow ER; Capaldo B; Conaway M; Gioeli DG; Weber MJ; Jameson MJ
Head Neck; 2015 Dec; 37(12):1722-32. PubMed ID: 24986420
[TBL] [Abstract][Full Text] [Related]
33. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
34. siRNA mediated the type 1 insulin-like growth factor receptor and epidermal growth factor receptor silencing induces chemosensitization of liver cancer cells.
Niu J; Li XN; Qian H; Han Z
J Cancer Res Clin Oncol; 2008 Apr; 134(4):503-13. PubMed ID: 17901981
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
36. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
[TBL] [Abstract][Full Text] [Related]
37. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells.
Yang L; Li J; Ran L; Pan F; Zhao X; Ding Z; Chen Y; Peng Q; Liang H
J Gastrointest Surg; 2011 Jun; 15(6):942-57. PubMed ID: 21479670
[TBL] [Abstract][Full Text] [Related]
39. Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors.
Weisheit S; Liebmann C
Cell Signal; 2012 Feb; 24(2):422-434. PubMed ID: 21964064
[TBL] [Abstract][Full Text] [Related]
40. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib.
Timpson P; Wilson AS; Lehrbach GM; Sutherland RL; Musgrove EA; Daly RJ
Cancer Res; 2007 Oct; 67(19):9304-14. PubMed ID: 17909038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
